Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

Bayer Says $7.6bn Farewell To Animal Health As It Sells Unit To Elanco

Bayer is relinquishing its Animal Health Unit to Elanco as the German major turns its focus more towards life sciences. The money received should help it pay down some Monsanto debt, but there are antitrust concerns.

Commercial Companies Deals

Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic

The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.

Financing StartUps and SMEs ImmunoOncology
Advertisement

Companies

Set Alert for Companies

Latest From Companies

Longer Intervals OK With ViiV's Injectable Anti-HIV Regimen

Topline results from the Phase III ATLAS-2M study indicate that injections every two months of ViiV/Janssen’s two-drug anti-HIV regimen are non-inferior to a once-monthly injectable regimen.

 

Infectious Diseases Clinical Trials

Synlogic Pivots After First Clinical Failure

The synthetic biotics company is discontinuing development of SNYB1020, its first clinical-stage product, which failed to lower blood ammonia in cirrhosis patients.

Research and Development Strategies Clinical Trials

AstraZeneca’s Imfinzi-Treme Checkpoint Inhibitor Combination Fails Again In NSCLC

The Phase III NEPTUNE lung cancer trial found the combination of Imfinzi and tremelimumab was no better than chemotherapy at extending overall survival. After repeat setbacks, AstraZeneca is now running out of opportunities to show its dual checkpoint blockade is effective in NSCLC.

Clinical Trials Companies

Big Pharma Nibbles As Turkey’s Localization Policy Yields Limited Results

The Turkish Government’s carrot-and-stick “localization” policy has started to yield results with some multinational pharma companies including GSK and Sanofi disclosing joint production ventures with local companies, but these ventures have been limited by difficult economic conditions and worsening investment environment, and the fixed euro rate.

Turkey Manufacturing

Oxurion's Anti-PIGF Antibody Disappoints in Diabetic Macular Edema

The primary endpoint was missed in a Phase IIa study of Oxurion’s THR-317 in diabetic macular edema, but vision did improve in two patient subgroups.

 

Ophthalmic Clinical Trials

AZ's Dapagliflozin Impresses In Topline Phase III Heart Failure Study

AstraZeneca’s SGLT2 inhibitor has grabbed attention for its potential role in chronic heart failure patients, with or without type 2 diabetes, following initial results from the DAPA-HF study.

 

Clinical Trials Market Intelligence
See All

Deals

Set Alert for Deals

Latest From Deals

Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines

Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.

Financing Business Strategies

Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol

Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.

Approvals Cancer

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Start-Up Quarterly Statistics: Financings Fell 17% To $2.84bn In Q2

A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.

Deals Financing

Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Asia Pacific Commercial

Finance Watch: Landos Raises $60m Series B Round Ahead Of Phase II Data In 2020

If Landos goes public late next year, its financing strategy will align with venture capital and IPO trends observed in a new Jefferies report. Also, D&D Pharmatech raises $137.1m in VC cash, Sonnet secures up to $100m and the CF Foundation commits up to $15m to Arcturus.

Financing Business Strategies
See All

Strategy

Set Alert for Strategy

Latest From Strategy

Can Dr Reddy’s Carve Into Crowded Indian Avastin Biosimilar Market?

Dr Reddy’s debuts biosimilar bevacizumab in India but can the significant price differential for one strength of the product help it gnaw into a competitive market?

Commercial Strategy

US Is Land Of Opportunity For Zealand

The Danish group is beefing up its operations across the Atlantic as it prepares filings for dasiglucagon and glepaglutide.

Metabolic Disorders Strategy

Interview: Mereo All Set For Key Setrusumab Data

Although far from a one-product company, data in Q4 will be key to whether the brittle bone drug could become a blockbuster for the UK NASDAQ-listed biotech.

Strategy Orthopedics

Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation

Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.

Commercial Strategy

Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Asia Pacific Commercial

Sun’s Ilumya Ramps Up In Skyrizi’s Shadow

Patient numbers and prescriptions in the US for Sun’s psoriasis therapy Ilumya are steadily on the rise, and the Indian firm said that the arrival of AbbVie’s rival Skyrizi hasn’t adversely impacted its formulary position.

Commercial Strategy
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Amgen's US Biosimilar Launches Are Off To A Steady Start, With A Big Coverage Decision

United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.

Biosimilars Launches

Sage's Zulresso Launch Is Off, But Not Running

The company updated investors on the launch of the first treatment for postpartum depression during its Q2 earnings call. More than 100 sites have been certified under the REMS.

Launches Neurology

Want To Fly In China‘s New Normal? Learn From Merck

Many multinationals are banking on novel drug products to capture China’s new growth spurt as it transforms to care centered on innovative therapies, although this could be a hard sell given the largely private pay nature of the market for such products. Q2 China growth at Merck & Co. however flew through the roof with the aid of a suite of newly launched products. So what made it a shining star?

China Commercial
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Big Pharma Nibbles As Turkey’s Localization Policy Yields Limited Results

The Turkish Government’s carrot-and-stick “localization” policy has started to yield results with some multinational pharma companies including GSK and Sanofi disclosing joint production ventures with local companies, but these ventures have been limited by difficult economic conditions and worsening investment environment, and the fixed euro rate.

Turkey Manufacturing

AZ's Dapagliflozin Impresses In Topline Phase III Heart Failure Study

AstraZeneca’s SGLT2 inhibitor has grabbed attention for its potential role in chronic heart failure patients, with or without type 2 diabetes, following initial results from the DAPA-HF study.

 

Clinical Trials Market Intelligence

Janssen's Imbruvica Leads CLL Market Expansion In Europe

Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.

 

Market Intelligence Cancer
See All
UsernamePublicRestriction

Register